Cancer Biological Therapy Market Size By Product (Monoclonal Antibodies {Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies}, Vaccines {Preventive Vaccines, Therapeutic Vaccines}, Cancer Growth Blockers {Tyrosine Kinase Inhibitors, Proteasome Inhibitors, mTOR Inhibitors}, Blood Cell Growth Factors {Lenograstim, Filgrastim}, Cytokine {Interferon, Interleukin}), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, India, China, Japan, Brazil, Argentina, Mexico, South Africa, Saudi Arabia, UAE), Application Potential, Competitive Market Share & Forecast, 2018 – 2024

Latest Update: Dec 2018 |  Published Date: Jul 2016 | 200 Pages | Report ID: GMI676 | Authors: Sumant Ugalmugale Report Format: PDF

  Request Sample Inquiry Before Buying
Summary Table of Contents Industry Coverage Methodology Customize this Report

Industry Trends

Cancer biological therapy market size was valued at USD 69.1 billion in 2017 and is expected to witness 6.8% CAGR from 2018 to 2024.
 

U.S. Cancer Biological Therapy Market, By Product, 2017 & 2024 (USD Million)
U.S. Cancer Biological Therapy Market, By Product, 2017 & 2024 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Rising prevalence of cancer worldwide is the key factor that will drive cancer biological therapy business growth during the forecast period. According to WHO cancer is the second leading cause of death worldwide, accounting for more than 9.5 million deaths in 2018. Additionally, prevalence of cancer is estimated to increase by 50% in 2020. Increasing consumption of alcohol and tobacco have led to rise in global cancer burden thereby surging cancer biological therapy industry growth.
 

Growing R&D investments by key industry players in cancer biological therapy will augment industry growth in near future. Furthermore, increasing healthcare expenditure and growing awareness about cancer has stimulated demand for effective cancer treatment. Technological advancements in oncology will further favor business growth. However, high cost and complications associated with anti-cancer drug therapy may impede cancer biological therapy market growth in coming years.
 

Cancer Biological Therapy Market, By Product

Vaccines segment is estimated to witness lucrative CAGR of 10.9% during the forecast timeframe owing to worldwide increasing prevalence of cancer coupled with rising awareness regarding preventive measures for cancer. Growing demand for preventive vaccines such as human papilloma vaccines (HPV) and hepatitis B vaccines (HBV) will drive the segmental growth. Moreover, utilization of therapeutic cancer vaccines to inhibit growth of relapsed tumors that are refractory to surgery, radiation therapy and chemotherapy will further foster segmental growth during the forecast timeline.
 

Monoclonal antibodies segment accounted over 34% revenue share in 2017 and is projected to show significant growth during the forecast period. Ability of monoclonal antibodies for targeting specific proteins on the cell surface will increase its adoption in cancer treatment. Furthermore, increasing patient preference towards advanced cancer biological therapy to avoid risks associated with anti-cancer drug therapy will further augment segmental growth over the coming years.
 

Germany Cancer Biological Therapy Market Size, By Vaccines, 2017 (USD Million)
Germany Cancer Biological Therapy Market Size, By Vaccines, 2017 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Cancer Biological Therapy Market, By Region

North America cancer biological therapy market accounted for USD 28.4 billion revenue in 2017 and is expected to witness considerable growth during the forecast period. Rising incidences of cancer in the region coupled with increasing geriatric population base will drive business growth. Technological advancement in cancer therapies, increasing R&D initiatives by industry players and government support towards development of advanced cancer therapies will favor industry growth. Awareness among people regarding cancer treatment, high healthcare expenditure and availability of advanced infrastructure will stimulate North America cancer biological therapy industry growth over the forecast period.
 

Europe cancer biological therapy market held significant revenue share in 2017 and is anticipated to show 5.8% CAGR over the analysis timeframe. Increasing burden of cancer in the region, presence of huge elderly patient pool and developments in cancer therapies will foster business growth. Rapidly evolving techniques in molecular biology, sophistication in health care as well as improvements and innovative approaches in technology will propel the industry growth over the forecast period. Rising number of initiatives to promote the value of effective cancer treatment will further favor Europe cancer biological therapy industry growth.

 

Asia Pacific Cancer Biological Therapy Market Size, By Country, 2024 (USD Million)
Asia Pacific Cancer Biological Therapy Market Size, By Country, 2024 (USD Million)

Get more details on this report - Request Free Sample PDF

 

Competitive Market Share

Some of the major industry players operating in the cancer biological therapy market include AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Celgene Corporation, Eisai, ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Incyte, Merck, Novartis, Otsuka, Pfizer, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals and Takeda Pharmaceuticals. The industry players primarily focus on implementing several strategic initiatives including new product launch, acquisition and mergers that help them in strengthening their existing market position. For instance, in December 2018, GlaxoSmithKline announced acquisition of TESARO, an oncology-focused biopharmaceutical company. This acquisition will help company to enhance its oncology business and foster company’s growth.
 

Cancer Biological Therapy Industry Background

Cancer Biological Therapy Market
Get more details on this report - Request Free Sample PDF
 

Immunization was discovered more than 200 years ago, that marks the beginning of biological therapy. Centuries ago, a surgeon in New York, William Coley, started using biological therapy to treat cancer patients. However, some people appeared to enter remission after developing certain bacterial infections. He then injected cancer patients with live bacteria, and later with filtered toxins. This method of treatment known as Coley's toxins was used for decades. Further, Paul Ehrlich, won Nobel Prize in 1908, for postulating that the surfaces of cells carried, side chains or receptor molecules. According to him, antibodies attached to the side chains caused the release of antitoxins. He further worked on developing antibodies that could target invaders. Later, the 1980s witnessed encouraging results of interferon usage to treat hairy-cell leukemia, a rare blood disorder. The FDA approved interferon used in this disease and was further used in the treatment of AIDS-related Kaposi's sarcoma, chronic myelogenous leukemia as well as genital warts.
 

Recently, Steven Rosenberg a researcher at the U.S. National Cancer Institute, discovered the ability of directing human body to discriminate between cancerous cells and healthy ones. In 1992, FDA approved genetically engineered IL-2 for use in advanced kidney cancer treatment. Further, clinical trials to determine the use of interleukin (IL-12) against AIDS and metastatic cancer were started in 1994. With the advent of technological advancement and better understanding of the biology of cancer cells, focus on development of biologic agents to control cell growth has increased in the recent years. Growing R&D investment and favorable government policies to support cancer treatment will drive cancer biological therapy industry growth in foreseeable future.
 


What Information does this report contain?

Historical data coverage: 2013 to 2017; Growth Projections: 2018 to 2024.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.


Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability

Why Global Market Insights?

 Comprehensive Research
  • All-inclusive coverage
  • In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
  • Penetrative insights & latest trends
  • Offers holistic understanding of the market
 Data Accuracy & Reliability
  • Unique methodology
  • Iterative in nature to eliminate errors
  • Detailed methodology, scope, assumptions and data sources available for reference
 Post-Sales Support
  • Committed to making a positive difference for our clients
  • Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
  • Every purchase comes with an option to obtain additional information:
    • up to 10% of the original cost
    • 45-minute analyst tele-call to obtain further clarity on the market.
 Security & Confidentiality
  • Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
  • Only PCI-DSS compliant payment methods used for highest level of client data security
This site is protected by Trustwave's Trusted Commerce program Authorize.Net Merchant - Click to Verify

Connect with our sales team

Chat With Us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info. I Agree